The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy
REVIEW|Updated:2025-12-13
|
The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy
“Advancements in single-cell and spatial transcriptomics have enabled a detailed molecular comprehension of the complex regulation of cell fate, significantly contributing to the development of personalized medicine. This review outlines the significance of single-cell RNA sequencing (scRNA-seq) in prostate cancer research, highlighting key molecular targets for diagnosis, treatment, and drug resistance characteristics. These studies are expected to provide novel insights for the development of immunotherapy and other innovative treatment strategies for castration-resistant prostate cancer.”
Military Medical ResearchVol. 12, Issue 2, Pages: 220-241(2025)
Affiliations:
1.Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
2.Division of Surgery & Interventional Science, University College London, London WC1E 6BT, UK
Cite this article as: Feng DC, Zhu WZ, Wang J, Li DX, Shi X, Xiong Q, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res. 2024;11(1):21.
DOI:
Cite this article as: Feng DC, Zhu WZ, Wang J, Li DX, Shi X, Xiong Q, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res. 2024;11(1):21. DOI: 10.1186/s40779-024-00526-7.
The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy
Leveraging artificial intelligence for clinical decision support in personalized standard regimen recommendation for cancer
Performance of GPT-4 for automated prostate biopsy decision-making based on mpMRI: a multi-center evidence study
Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021
ADP-dependent glucokinase: the ancient, archaeal key to prostate cancer
Advancing skeletal health and disease research with single-cell RNA sequencing
Related Author
Ya-Le Jiang
Guo Zhao
Shu-Hang Wang
Ning Li
Ming-Jun Shi
Zhi-Xiang Wang
Shuang-Kun Wang
Xuan-Hao Li
Related Institution
Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Division of Science and Technology, Beijing Friendship Hospital, Capital Medical University
Department of Urology, Beijing Miyun District Traditional Chinese Medicine Hospital
Department of Urology, Beijing Fuxing Hospital, Capital Medical University
Department of Urology, Peking University Third Hospital